guest ::
| Home > Publications Database > Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. > print |
| Home > Publications Database > Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. > print |
| 001 | 137808 | ||
| 005 | 20240321220323.0 | ||
| 024 | 7 | _ | |a 10.1212/WNL.0000000000001312 |2 doi |
| 024 | 7 | _ | |a pmid:25653290 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6170184 |2 pmc |
| 024 | 7 | _ | |a 0028-3878 |2 ISSN |
| 024 | 7 | _ | |a 1526-632X |2 ISSN |
| 024 | 7 | _ | |a altmetric:3401942 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-04130 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Brüggemann, Norbert |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. |
| 260 | _ | _ | |a [S.l.] |c 2015 |b Ovid |
| 264 | _ | 1 | |3 online |2 Crossref |b Ovid Technologies (Wolters Kluwer Health) |c 2015-02-04 |
| 264 | _ | 1 | |3 print |2 Crossref |b Ovid Technologies (Wolters Kluwer Health) |c 2015-03-03 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1588685551_1067 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Deep brain stimulation of the internal pallidum (GPi-DBS) is an established therapeutic option in treatment-refractory dystonia, and the identification of factors predicting surgical outcome is needed to optimize patient selection.In this retrospective multicenter study, GPi-DBS outcome of 8 patients with DYT6, 9 with DYT1, and 38 with isolated dystonia without known monogenic cause (non-DYT) was assessed at early (1-16 months) and late (22-92 months) follow-up using Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) scores.At early follow-up, mean reduction of dystonia severity was greater in patients with DYT1 (BFMDRS score: -60%) and non-DYT dystonia (-52%) than in patients with DYT6 dystonia (-32%; p = 0.046). Accordingly, the rate of responders was considerably lower in the latter group (57% vs >90%; p = 0.017). At late follow-up, however, GPi-DBS resulted in comparable improvement in all 3 groups (DYT6, -42%; DYT1, -44; non-DYT, -61%). Additional DBS of the same or another brain target was performed in 3 of 8 patients with DYT6 dystonia with varying results. Regardless of the genotype, patients with a shorter duration from onset of dystonia to surgery had better control of dystonia postoperatively.Long-term GPi-DBS is effective in patients with DYT6, DYT1, and non-DYT dystonia. However, the effect of DBS appears to be less predictable in patients with DYT6, suggesting that pre-DBS genetic testing and counseling for known dystonia gene mutations may be indicated. GPi-DBS should probably be considered earlier in the disease course.This study provides Class IV evidence that long-term GPi-DBS improves dystonia in patients with DYT1, DYT6, and non-DYT dystonia. |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 2 | |a Adolescent |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Child |2 MeSH |
| 650 | _ | 2 | |a Child, Preschool |2 MeSH |
| 650 | _ | 2 | |a Deep Brain Stimulation: methods |2 MeSH |
| 650 | _ | 2 | |a Deep Brain Stimulation: trends |2 MeSH |
| 650 | _ | 2 | |a Dystonia: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Dystonia: therapy |2 MeSH |
| 650 | _ | 2 | |a Electrodes, Implanted |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Follow-Up Studies |2 MeSH |
| 650 | _ | 2 | |a Globus Pallidus: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Treatment Outcome |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 700 | 1 | _ | |a Kühn, Andrea |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Schneider, Susanne A |b 2 |
| 700 | 1 | _ | |a Kamm, Christoph |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Wolters, Alexander |b 4 |
| 700 | 1 | _ | |a Krause, Patricia |b 5 |
| 700 | 1 | _ | |a Moro, Elena |b 6 |
| 700 | 1 | _ | |a Steigerwald, Frank |b 7 |
| 700 | 1 | _ | |a Wittstock, Matthias |b 8 |
| 700 | 1 | _ | |a Tronnier, Volker |b 9 |
| 700 | 1 | _ | |a Lozano, Andres M |b 10 |
| 700 | 1 | _ | |a Hamani, Clement |b 11 |
| 700 | 1 | _ | |a Poon, Yu-Yan |b 12 |
| 700 | 1 | _ | |a Zittel, Simone |b 13 |
| 700 | 1 | _ | |a Wächter, Tobias |0 P:(DE-2719)9000333 |b 14 |u dzne |
| 700 | 1 | _ | |a Deuschl, Günther |b 15 |
| 700 | 1 | _ | |a Krüger, Rejko |0 P:(DE-2719)2811170 |b 16 |u dzne |
| 700 | 1 | _ | |a Kupsch, Andreas |b 17 |
| 700 | 1 | _ | |a Münchau, Alexander |b 18 |
| 700 | 1 | _ | |a Lohmann, Katja |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Volkmann, Jens |b 20 |
| 700 | 1 | _ | |a Klein, Christine |b 21 |
| 773 | 1 | 8 | |a 10.1212/wnl.0000000000001312 |b : Ovid Technologies (Wolters Kluwer Health), 2015-02-04 |n 9 |p 895-903 |3 journal-article |2 Crossref |t Neurology |v 84 |y 2015 |x 0028-3878 |
| 773 | _ | _ | |a 10.1212/WNL.0000000000001312 |g Vol. 84, no. 9, p. 895 - 903 |0 PERI:(DE-600)1491874-2 |n 9 |q 84:9<895 - 903 |p 895-903 |t Neurology |v 84 |y 2015 |x 0028-3878 |
| 856 | 7 | _ | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170184 |
| 909 | C | O | |o oai:pub.dzne.de:137808 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)9000333 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2811170 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |2 G:(DE-HGF)POF3-300 |v Population Studies and Genetics |x 0 |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROLOGY : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEUROLOGY : 2017 |
| 920 | 1 | _ | |0 I:(DE-2719)5000058 |k Ext UKT |l Ext Universitätsklinikum Tübingen |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser 1 |l Parkinson Genetics |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)5000058 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|